Bharat Biotech gets DCGI nod to test intradermal vaccine delivery |
Clinical News
eMediNexus Coverage from: 
Bharat Biotech gets DCGI nod to test intradermal vaccine delivery

5 Read Comments                

NEW DELHI: Bharat Biotech has received approval from the Drugs Controller General of India to test the administration of its experimental COVID-19 vaccine through skin, i.e., intradermal vaccine delivery.

If it is proven to be effective, this could help more people get the vaccination and could also reduce the vaccine cost as this process will need lesser amount of vaccine. Intradermal delivery will be investigated separately, alongside the clinical trials that are currently underway for the vaccine candidate. With this nod, Bharat Biotech has become the first Indian company to test a vaccine candidate in both intradermal and intramuscular routes… (ET Healthworld, August 22, 2020)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now